CN119053604A - 用于治疗erk5介导的疾病的杂环化合物 - Google Patents

用于治疗erk5介导的疾病的杂环化合物 Download PDF

Info

Publication number
CN119053604A
CN119053604A CN202380034888.8A CN202380034888A CN119053604A CN 119053604 A CN119053604 A CN 119053604A CN 202380034888 A CN202380034888 A CN 202380034888A CN 119053604 A CN119053604 A CN 119053604A
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
solvate
acceptable salt
compound
hydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380034888.8A
Other languages
English (en)
Chinese (zh)
Inventor
萨姆·巴特沃斯
奥利弗·理查德·史密斯
查尔斯·尼古拉斯·乔治·埃文斯
凯瑟琳·乔治娜·法恩根
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Original Assignee
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Ltd filed Critical Cancer Research Technology Ltd
Publication of CN119053604A publication Critical patent/CN119053604A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202380034888.8A 2022-02-18 2023-02-17 用于治疗erk5介导的疾病的杂环化合物 Pending CN119053604A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2202199.2 2022-02-18
GBGB2202199.2A GB202202199D0 (en) 2022-02-18 2022-02-18 Compounds
PCT/GB2023/050369 WO2023156791A1 (en) 2022-02-18 2023-02-17 Heterocyclic compounds useful for treating a erk5-mediated disease

Publications (1)

Publication Number Publication Date
CN119053604A true CN119053604A (zh) 2024-11-29

Family

ID=80934460

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380034888.8A Pending CN119053604A (zh) 2022-02-18 2023-02-17 用于治疗erk5介导的疾病的杂环化合物

Country Status (8)

Country Link
US (1) US20250154157A1 (cg-RX-API-DMAC7.html)
EP (1) EP4479400B1 (cg-RX-API-DMAC7.html)
JP (1) JP2025508435A (cg-RX-API-DMAC7.html)
CN (1) CN119053604A (cg-RX-API-DMAC7.html)
AU (1) AU2023220934A1 (cg-RX-API-DMAC7.html)
CA (1) CA3251985A1 (cg-RX-API-DMAC7.html)
GB (1) GB202202199D0 (cg-RX-API-DMAC7.html)
WO (1) WO2023156791A1 (cg-RX-API-DMAC7.html)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CA2242425C (en) 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
EE05345B1 (et) 1999-02-10 2010-10-15 Astrazeneca Ab Kinasoliini derivaadid angiogeneesi inhibiitoritena
BR0111230A (pt) 2000-05-31 2003-06-10 Astrazeneca Ab Composto, e, uso e processo para a preparação do mesmo
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
EE200300015A (et) 2000-07-07 2004-10-15 Angiogene Pharmaceuticals Limited Kolhinooli derivaadid kui angiogeneesi inhibiitorid
KR20030014425A (ko) 2000-07-07 2003-02-17 앤지오젠 파마슈티칼스 리미티드 혈관 손상제인 콜치놀 유도체
WO2015117083A1 (en) * 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Diazepane derivatives and uses thereof
EP3099693A4 (en) * 2014-01-31 2017-08-16 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
WO2015129927A1 (en) * 2014-02-26 2015-09-03 Kyorin Pharmaceutical Co., Ltd. Heterocyclic compounds
AU2020356484A1 (en) 2019-09-27 2022-03-17 Dana-Farber Cancer Institute, Inc. ERK5 degraders as therapeutics in cancer and inflammatory diseases

Also Published As

Publication number Publication date
AU2023220934A1 (en) 2024-08-29
EP4479400B1 (en) 2026-08-19
JP2025508435A (ja) 2025-03-26
GB202202199D0 (en) 2022-04-06
EP4479400A1 (en) 2024-12-25
CA3251985A1 (en) 2023-08-24
US20250154157A1 (en) 2025-05-15
WO2023156791A1 (en) 2023-08-24

Similar Documents

Publication Publication Date Title
JP7762957B2 (ja) Ｍｅｔｔｌ３阻害化合物
JP7536949B2 (ja) Ｒｅｔ阻害剤として有用な化合物
ES2975690T3 (es) Inhibidores de BCL6 derivados de benzimidazolona
US11453666B2 (en) Autotaxin inhibitory compounds
US11787786B2 (en) Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor 1
KR102604942B1 (ko) 증식성 장애의 치료에 사용하기 위한 트리사이클릭 화합물
CN106459035B (zh) N2‑苯基‑吡啶并[3,4‑d]嘧啶‑2,8‑二胺衍生物及其作为mps1抑制剂的用途
ES2898423T3 (es) Derivados de quinolina como inhibidores de la actividad de la vía del factor de choque térmico 1
JP2019515903A (ja) Ｒｅｔキナーゼ阻害剤としての複素環化合物
JP2017538750A (ja) Ｐａｒｇ阻害化合物
AU2012228090A1 (en) Pyrrolopyridineamino derivatives as Mps1 inhibitors
JP2026500923A (ja) 阻害性化合物
CN104968343A (zh) 吲哚衍生物
US20250154157A1 (en) Heterocyclic compounds useful for treating a erk5-mediated disease
HK1245253B (en) Parg inhibitory compounds

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination